Researchers at UT MD Anderson Cancer Center have developed a blood-based biomarker that can identify asymptomatic Lynch Syndrome patients at higher cancer risk. This early immune detection method enables personalized risk stratification for improved
← News
Public Health Systems Public Health Systems Health
Blood-based biomarker could help stratify cancer risk in Lynch Syndrome
Blood-Based Biomarker Discovery
Lynch Syndrome Patients Target population
Risk Stratification Key benefit
Immune Signatures Detection method
Immune Detection Signatures mechanism
Asymptomatic LS Patients application
Personalized Prevention significance